1407830-91-4

Basic information

• Product Name: 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-(4R)-1,4-dimethyl-8-(2-methyl-2H-1,2,3-triazole-4-yl)-6-(4-chloro-phenyl)
• Synonyms: 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-(4R)-1,4-dimethyl-8-(2-methyl-2H-1,2,3-triazole-4-yl)-6-(4-chloro-phenyl)
• CAS NO: 1407830-91-4
• Molecular Weight: 405.89
• Mol File: 1407830-91-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-(4R)-1,4-dimethyl-8-(2-methyl-2H-1,2,3-triazole-4-yl)-6-(4-chloro-phenyl)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-(4R)-1,4-dimethyl-8-(2-methyl-2H-1,2,3-triazole-4-yl)-6-(4-chloro-phenyl)(1407830-91-4)
• EPA Substance Registry System: 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-(4R)-1,4-dimethyl-8-(2-methyl-2H-1,2,3-triazole-4-yl)-6-(4-chloro-phenyl)(1407830-91-4)

Safety Data

• Hazardous Substances Data: 1407830-91-4(Hazardous Substances Data)

Upstream product

• 16681-67-7 4-bromo-2-methyl-2H-1,2,3-triazole 
• 1407834-44-9 (4R)-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine, 5,6-dihydro-1,4-dimethyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(4-chloro-phenyl) 
• 1407832-40-9 8-bromo-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4Hbenzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 
• 1407833-64-0 5,6-dihydro-1,4-dimethyl-8-bromo-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine 
• 1407833-60-6 7-bromo-3-methyl-4,5-dihydro-1H-benzo[b] [1,4] diazepine-2(3H)-thione 
• 1407833-56-0 7-bromo-3-methyl-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one 
• 1407833-52-6 methyl 3-(2-amino-5-bromophenylamino)-2-methylpropanoate 
• 1407833-48-0 methyl 3-(5-bromo-2-nitrophenylamino)-2-methylpropanoate 
• 1407830-61-8 (R)-8-bromo-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4Hbenzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 

Relevant articles and documents

BROMODOMAIN INHIBITORS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.